Emma Essock-Burns1,2, Janine M. Lupo1, Susan M. Chang3, Soonmee Cha1,3, Sarah J. Nelson1,2
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA; 2UCSF/UCB Joint Graduate Group in Bioengineering, University of California, San Francisco, San Francisco, CA, USA; 3Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Perfusion parameters, derived from T1-weighted dynamic contrast enhanced imaging and arterial spin labeling, of tumor and normal brain tissue in patients with GBM were tracked for 6 months after receiving anti-angiogenic therapy. Kps, fBV, and CBF levels in the tumor region were seen to decrease significantly 6 months after treatment with noticeable changes within individual patients by 2 months after treatment. The results from this study suggest that perfusion imaging is a useful tool for assessing the effects of this therapy and possibly assisting early prediction of progression for patients with GBM.